Breast Cancer Clinical Trial

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Summary

Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type for which the patient was eligible and willing to receive.
Adequate bone marrow, kidney and liver function
Performance status of 0 or 1.
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

Exclusion Criteria:

• Prior treatment targeting LAIR1

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

71

Study ID:

NCT05311618

Recruitment Status:

Active, not recruiting

Sponsor:

NGM Biopharmaceuticals, Inc

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

SCRI Denver
Denver Colorado, 80218, United States
Yale Cancer Center
New Haven Connecticut, 06520, United States
Henry Ford Health System
Detroit Michigan, 48202, United States
START Midwest
Grand Rapids Michigan, 49546, United States
Mount Sinai Hospital
New York New York, 10029, United States
MD Anderson
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

71

Study ID:

NCT05311618

Recruitment Status:

Active, not recruiting

Sponsor:


NGM Biopharmaceuticals, Inc

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.